Angion Biomedica Corp (ANGN): Price and Financial Metrics
ANGN Price/Volume Stats
| Current price | $10.00 | 52-week high | $10.60 |
| Prev. close | $0.98 | 52-week low | $0.46 |
| Day low | $8.90 | Volume | 22,480 |
| Day high | $10.60 | Avg. volume | 86,718 |
| 50-day MA | $0.71 | Dividend yield | N/A |
| 200-day MA | $0.82 | Market Cap | 301.14M |
ANGN Stock Price Chart Interactive Chart >
Angion Biomedica Corp (ANGN) Company Bio
Angion Biomedica Corp. operates as a late-stage biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica serves customers in the State of New York.
Latest ANGN News From Around the Web
Below are the latest news stories about ANGION BIOMEDICA CORP that investors may wish to consider to help them evaluate ANGN as an investment opportunity.
Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite RiskyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Angion (ANGN) Down on Merger Agreement With Private BiotechAngion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off Tuesday with a look at the biggest pre-market stock movers that traders will want to keep an eye on today! |
Elicio Therapeutics and Angion Enter into Definitive Merger AgreementMerger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLO |
Bullish insiders bet US$857k on Angion Biomedica Corp. (NASDAQ:ANGN)Multiple insiders secured a larger position in Angion Biomedica Corp. ( NASDAQ:ANGN ) shares over the last 12 months... |
ANGN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 44.05% |
| 3-year | -92.48% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -72.01% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...